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OBJECTIVE — To determine if glucose and C-peptide values obtained as part of the Hyper-
glycemia and Adverse Pregnancy Outcome (HAPO) study could be used to estimate insulin
sensitivity during late pregnancy.
RESEARCH DESIGN AND METHODS — A total of 78 women enrolled in the HAPO
study were recruited for this ancillary study. Venous plasma samples were drawn after an 8- to
10-h fast (time 0) and at 30, 60, 90, and 120 min after a 75-g glucose challenge, which was
performed at 24–32 weeks’ gestation. Samples were analyzed for plasma glucose, insulin, and
C-peptide.InsulinsensitivitywasestimatedusingtheestablishedMatsudaandDeFronzoinsulin
sensitivity index for oral glucose tolerance tests (ISOGTT). Insulin sensitivity was also calculated
from two other commonly used indexes of insulin sensitivity (that for homeostasis model
assessment [ISHOMA] and that for quantitative insulin sensitivity check index [ISQUICKI]). A new
insulin sensitivity index was calculated using the glucose and C-peptide concentrations at 0 and
60 min to derive ISHOMA C-pep,I S QUICKI C-pep, and ISOGTT C-pep. These indexes were then
correlated with insulin sensitivity estimated from the ISOGTT.
RESULTS — The strongest correlation with the ISOGTT was obtained for ISOGTT C-pep (r 
0.792,P0.001).Further,thecorrelationsofISHOMA C-pepandISQUICKI C-pepwithISOGTTwere
also signiﬁcant (r  0.676, P  0.001 and r  0.707, P  0.001, respectively).
CONCLUSIONS — These data suggest that calculated ISOGTT C-pep is an excellent predictor
of insulin sensitivity in pregnancy and can be used to estimate insulin sensitivity in over 25,000
women participating in the HAPO study.
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G
estational diabetes mellitus (GDM)
is a common metabolic disorder
in developed countries occurring
in 2–10% of pregnancies (1). GDM is
associated with an increased risk of ma-
ternal and perinatal complications such
as preeclampsia, macrosomia, shoulder
dystocia, and neonatal hypoglycemia.
Furthermore, the offspring of GDM
pregnancies have an increased risk of
obesity and type 2 diabetes in later life
(2,3). In a recent study, Crowther et al.
(4) reported that treatment of GDM in
the form of dietary advice, blood glu-
cose monitoring, and insulin therapy as
required for glycemic control reduces
the rate of serious perinatal complica-
tions. Although the risks associated
with GDM are well recognized, there
has been no general agreement about
which glucose criteria should be used
for diagnosis of GDM based primarily
on maternal perinatal and neonatal
outcomes.
The recently completed Hyperglyce-
mia and Adverse Pregnancy Outcome
(HAPO) study was a prospective observa-
tionalstudyduringwhich25,000preg-
nant women in 10 different countries
were recruited to determine the levels of
glycemia, less severe than diabetes, asso-
ciated with risks of large for gestational
age, clinical neonatal hypoglycemia,
cord-bloodC-peptide,andprimarycesar-
ean delivery (5) as well as neonatal adi-
posity (6). The results conﬁrm that there
is a strong continuous association be-
tween maternal glucose concentrations
below those currently used to diagnose
GDM and adverse perinatal outcomes.
Normal human pregnancy is charac-
terized by a signiﬁcant decrease in insulin
sensitivity (7). Furthermore, women de-
veloping GDM in addition to an inade-
quate insulin response have decreased
insulin sensitivity compared with women
with normal glucose tolerance (8). In
many of these studies, insulin sensitivity
has been estimated using a euglycemic-
hyperinsulinemicclamp,whichisconsid-
eredthegoldstandardmethod.However,
theclampisacomplicated,high-cost,and
labor-intensive procedure and is not suit-
able for large studies.
Various investigators have validated
indexesofinsulinsensitivityderivedfrom
an oral glucose tolerance test (ISOGTT) (9)
or fasting glucose and insulin levels (that
for homeostasis model assessment
[ISHOMA] and that for quantitative insulin
sensitivity check index [ISQUICKI])
(10,11): in all these studies, only non-
pregnant adults were evaluated. How-
ever, we recently reported a study of
normal glucose tolerant and GDM preg-
nantwomen,comparingdifferentindexes
of insulin sensitivity derived from OGTTs
with hyperinsulinemic-euglycemic
clamps throughout pregnancy (12). We
concluded that during pregnancy, the
ISOGTT was the index that best correlated
with insulin sensitivity when compared
with the euglycemic-hyperinsulinemic
clamp (r  0.86, P  0.001). Hence, the
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insulin sensitivity could be reasonably es-
timated using glucose and C-peptide
measures obtained during a 75-g OGTT
in HAPO study subjects.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the MetroHealth’s Institutional
Review Board, and the Scientiﬁc Review
Committee of the General Clinical Re-
search Center (now the Clinical Research
Unit of the Clinical and Translational Sci-
enceAward)subjectswererecruitedfrom
women who had already formally agreed
to participate in the HAPO study. Each
subject signed a written consent form de-
scribing the ancillary research protocol.
None of the subjects or investigators was
made aware of the results of the HAPO
OGTT so as not to affect the outcome of
the primary project, unless fasting or 2-h
glucose values exceeded predeﬁned
thresholds.AftercompletionoftheHAPO
study and publication of the primary re-
sults, a post hoc analysis was performed
to assess the number of women in this
ancillary study who would have been di-
agnosed as having GDM using criteria es-
tablished by the Fourth International
GDM Workshop criterion (13).
A total of 78 women enrolled in the
HAPOstudywereevaluatedaspartofthis
ancillary study. None of the patients had
medical or obstetrical problems in a pre-
vious or the index pregnancy. A 75-g
HAPO OGTT was performed in all sub-
jects as close as possible to the 28th week
of gestation according to standardized
procedures (14): mean  SD gestational
age at recruitment was 27.6  1.2 weeks.
The OGTT was performed after an 8- to
10-h overnight fast. The HAPO OGTT
consistedoffastingand30-,60-,90-,and
120-min glucose measures and a fasting
and 60-min C-peptide determination. To
calculate the ISOGTT, plasma insulin was
also obtained at fasting and at 30, 60, 90,
and 120 min.
Plasma glucose concentrations were
measured by the glucose oxidase method
(Yellow Springs Instruments, Yellow
Springs, OH). Blood samples for insulin
measurements were centrifuged at 4°C
and stored at 70°C. Insulin and C-
peptide determinations were subse-
quently performed in duplicate on all
samples by a double-antibody radioim-
munoassay (Insulin: Linco, St. Louis,
MO; C-peptide: Diagnostic Products, Los
Figure1—Theresultsofthe75-gOGTT:A:Glucose.B:Insulin.C:C-peptide.Dataarepresented
as means  SD. n  78.
Table 1—Demographics of study population
Maternal
Age (years) 27.6  5.3
Height (cm) 163  7
Pre-pregnancy weight (kg) 73.7  20.3
Pre-pregnancy BMI (kg/m
2) 27.5  7.0
Parity
03 7
12 3
11 8
Race/ethnicity
Caucasian 58
African American 11
Hispanic 7
Asian 2
Data are means  SD or n.
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The glucose values are expressed in milli-
grams per deciliter, insulin as microunits
per milliliter, and C-peptide as picomoles
per liter.
The insulin sensitivity index was cal-
culatedfromtheOGTTaccordingtothree
different equations. The ﬁrst was the
equation described by Matsuda and De-
Fronzo (ISOGTT) (9): insulin sensitivity
was calculated as follows:
ISOGTT  10,000/FPG  FPI
 G  I
FPG and FPI are fasting plasma glucose
and fasting plasma insulin, respectively,
whereas G and I are mean glucose and
mean insulin from 0 to 120 min.
The second equation was described
by Matthews et al. (10) (ISHOMA), and in-
sulin sensitivity was calculated as follows:
ISHOMA  22.5/FPG  FPI
The last considered equation was pro-
posed by Katz et al. (11) and is called
ISQUICKI (Quantitative Insulin Sensitivity
Check Index):
ISQUICKI  1/log(FPI)  log(FPG)]
Insulin sensitivity indexes were then
calculated using glucose and C-peptide
concentrations available as part of the
standard HAPO OGTT, i.e., C-peptide
instead of insulin, at 0 and 60 min
(ISOGTT C-pep,I S HOMA C-pep, and
ISQUICKI C-pep). To have the units from
the estimates of insulin sensitivity from
the ISOGTT C-pep resemble those of the
ISOGTT, 500,000 was used as the nu-
merator rather than 10,000.
All data are presented as means 
SDs. Because ISOGTT is the index that
best correlated with insulin sensitivity
calculated from the euglycemic-
hyperinsulinemic clamp (12), we evalu-
atedthecorrelationbetweenISOGTT C-pep,
ISHOMA C-pep, and ISQUICKI C-pep with
ISOGTT using Pearson correlations and
linear regression analyses. Comparisons
between the normal glucose tolerant and
GDM groups were made using Mann-
Whitney U tests because of non-normal
distribution of the data. All analyses were
performed with Statistix, version 8.0
(Abacus Concepts, Berkeley, CA). A P
value 0.05 was considered signiﬁcant.
RESULTS— Maternal demographic
characteristicsofthestudypopulationare
presented in Table 1. Mean maternal pre-
gravid BMI was 26 kg/m
2, reﬂecting a
tendencytowardourstudysubjectsbeing
overweight and obese. The results of the
Figure2—TheregressionmodelsforISOGTTandISOGTT C-pep(A):y1.906	0.9x,r0.792,
P  0.001; ISHOMA C-pep (B): y  0.156 	 0.088x, r  0.676, P  0.001; and ISQUICKI C-pep (C):
y  0.397 	 0.008x, r  0.707, P  0.001, n  78.
Table 2—Estimates of insulin sensitivity
ISOGTT 3.456  1.678
ISOGTT C-pep 5.016  1.907
ISHOMA C-pep 2,680  1,293
ISQUICKI C-pep 0.212  0.009
Data are means  SD.
HAPO estimates of insulin sensitivity
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glucose,post-OGTTglucose,insulin,and
C-peptide levels are shown in Fig. 1A, B,
and C, respectively. Mean fasting glucose
was 83.5  6.5 mg/dl and mean fasting
insulin and C-peptide concentrations
were 16.0  8.1 
U/ml and 710  304
pmol/l, respectively. Six of the 78 (7.7%)
subjects had GDM as deﬁned by the
Fourth International Workshop Con-
ference on GDM criteria (13). The
mean  SD estimates of insulin sensi-
tivity for the ISOGTT,I S OGTT C-pep,
IS
HOMA C-pep,andISQUICKI C-pepareshownin
Table 2.
The correlations between insulin sensi-
tivity indexes (ISOGTT C-pep,I S HOMA C-pep,
and ISQUICKI C-pep) and ISOGTT are shown
in Fig. 2. ISOGTT C-pep (r  0.792, P 
0.001) had the strongest correlation
with the standard ISOGTT. In contrast, us-
ingthefastingglucoseandC-peptidedata,
the correlations of ISHOMA C-pep and
ISQUICKI C-pepwithISOGTTwerer0.676
(P  0.001) and r  0.707 (P  0.001),
beingweakercomparedwithISOGTT C-pep
(Fig. 2). There was a stronger association
(multiple r) when a squared term was
addedtotheregressionmodel;ISOGTT C-pep
(r  0.821, P  0.0001), ISHOMA C-pep
(multiple r  0.705, P  0.001), and
ISQUICKI C-pep (r  0.748, P  0.001),
but the relative strength of the relation-
ships to ISOGTT was similar to the cor-
relations from the simple linear models
(Fig. 3).
Last, there was a signiﬁcant inverse
correlation between maternal prepreg-
nancyBMIandISOGTT C-pep(r0.385,
P0.001),andthesixwomenwithGDM
had decreased insulin sensitivity com-
pared with women with normal glucose
tolerance (ISOGTT C-pep 2.86  1.16 vs.
5.20  1.85, P  0.0025).
CONCLUSIONS — Measurement of
insulin sensitivity in 25,000 HAPO sub-
jects using either the euglycemic-
hyperinsulinemic clamp or the intravenous
minimalmodeltechniquewasnotpossible.
We therefore elected to use the ISOGTT as
our reference standard, based on previous
work by Matsuda and DeFronzo showing
that the ISOGTT correlated well with the eu-
glycemic clamp in a large number of study
subjects having a wide range of age and
body size (9). Furthermore, we have previ-
ously shown (12) that during pregnancy,
the ISOGTT had the strongest correlation
with insulin sensitivity as measured by the
euglycemicclamp,adjustedforresidualhe-
patic glucose production. In this earlier
study,thecorrelationoftheISOGTTwithin-
sulin sensitivity in pregnancy measured by
clamp was r  0.86 (P  0.001). The cor-
relation during early pregnancy (12–14
weeks) was r  0.89 (P  0.001) and dur-
ing late pregnancy (34–36 weeks) was r 
0.80 (P  0.001). The correlation of the
ISOGTT with the clamp was also highly sig-
niﬁcant for both women with normal glu-
cose tolerance and women with GDM. One
of the strengths of the ISOGTT as a measure
of insulin sensitivity is that it incorporates
both basal and hepatic measures of insulin
sensitivity as well as post-absorptive or pe-
ripheral insulin sensitivity.
In the present study, the ISOGTT C-pep
proved to be the best predictor of insulin
Figure 3—The regression models for ISOGTT and ISOGTT C-pep (A): y  0.261 	 1.894x 
0.122x
2, multiple r  0.821; ISHOMA C-pep (B): y  0.016 	 0.192x  0.013x
2, multiple r 
0.705; and ISQUICKI C-pep (C): y  0.38 	 0.018x  0.001x
2, multiple r  0.748, n  78.
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ISOGTT as the reference measure of insulin
sensitivity. These data give us the conﬁ-
dence that the ISOGTT C-pep can provide im-
portant data regarding insulin sensitivity in
thegreaterHAPOpopulationandopensthe
possibility of developing large-scale meta-
bolicstudiesfromthedatageneratedinthis
cohort. The ISOGTT C-pep may also be a use-
ful tool because it includes the C-peptide
response to glucose and hence provides an
important measure of insulin secretion. As
noted by Matsuda and DeFronzo (9), the
ISOGTT provides a more robust measure of
insulin sensitivity in normoglycemic indi-
viduals compared with individuals with
type 2 diabetes. This may be related to the
greater insulin secretory capacity in normal
glucose tolerant individuals. Because nor-
mal pregnancy is associated with an in-
crease in insulin response (7), the inclusion
of a measure of insulin secretion such as in
theISOGTT C-pepmaybeadvantageousinas-
sessing metabolic function in the HAPO
cohort.
ISHOMA C-pep and ISQUICKI C-pep were
also used to estimate insulin sensitivity in
this study. ISHOMA is frequently used to
estimate insulin sensitivity in nonpreg-
nant individuals. The index is based on
the use of the fasting glucose and insulin.
The index assumes that the circulating
glucose and insulin are determined by a
feedback loop between the liver and pan-
creatic -cells. ISQUICKI is based on a log-
arithmic and reciprocal transformation of
a single fasting glucose and insulin value.
The model is similar to a HOMA model
and differs only in the treatment of the
data. In contrast to ISOGTT,I S HOMA and
ISQUICKI incorporate only basal or fasting
glucose and insulin measures and may be
more reﬂective of only hepatic insulin
sensitivity. Therefore, it is not surprising
that ISHOMA C-pep and ISQUICKI C-pep pro-
videdalessrobustestimateofinsulinsen-
sitivity compared with ISOGTT C-pep.
Supplementary Table 1, showing the
correlations between ISHOMA C-pep and
ISQUICKI C-pep in comparison with
ISHOMA,IS QUICKI,andISOGTT,isprovided
in an online appendix, available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1463/DC1. We observed similar
results when ISHOMA and ISQUICKI were
compared with the clamp measures dur-
ing pregnancy in our previous study.
A limitation of our protocol is that we
estimated HAPO pancreatic -cell function
using C-peptide at time 0 and 60 rather
than insulin. The reason for using C-
peptide rather than insulin was that with
over 25,000 maternal samples to be trans-
ported across continents, there was a risk
that some samples might be hemolyzed.
Hemolysisisknowntoincreaseinsulindeg-
radation but not to affect C-peptide (15).
Therefore, because insulin and C-peptide
are secreted in equimolar levels, we elected
to use C-peptide rather than insulin to esti-
mate insulin sensitivity.
In conclusion, this study conﬁrms that
amongthethreeproposedindexes,thebest
estimate of insulin sensitivity during preg-
nancy in the HAPO study subjects can be
obtained from the ISOGTT C-pep. The index
provides a reproducible and accurate mea-
sure of maternal metabolism during preg-
nancy. The ability to assess insulin
sensitivity in a large and diverse subject
population evaluated in the HAPO study
may aid in the assessment of the short- and
long-term affect of maternal metabolism on
the offspring and the potential of fetal pro-
gramming outcomes. Although these in-
dexes cannot replace more direct measures
of insulin sensitivity such as the euglycemic
clamp,ISOGTT C-pepcanbeconsideredarea-
sonable low-cost clinical parameter for as-
sessinginsulinsensitivityduringpregnancy
in the 25,000 subjects who participated in
the HAPO study.
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